MedPath

study to assess the efficacy of oral melatonin plus rectal indomethacin versus rectal indomethacin for the prevention of post-ercp pancreatitis

Recruiting
Conditions
Cholangitis, (2) ICD-10 Condition: K87||Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere, (3) ICD-10 Condition: K831||Obstruction of bile duct,
Registration Number
CTRI/2021/03/032127
Lead Sponsor
BSBY Scheme Govt of Rajasthan
Brief Summary

It will be a prospective, Randomized Controlled comparative study to assess the efficacy of Oral Melatonin plus Rectal Indomethacin versus Rectal Indomethacin for the prevention of Post Ercp Pancreatitis.

All the patients fulfilling the inclusion criteria  will be randomized into two groups . Primary and secondary end points will be studied.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
300
Inclusion Criteria

ALL PATIENTS UNDERGOING ERCP IN THE DEPARTMENT OF GASTROENTEROLOGY, SMS HOSPITAL OVER A PERIOD OF 6 MONTHS.

Exclusion Criteria
    1. History of hypersensitivity to Indomethacin 2) History of hypersensitivity to Melatonin 3) Recent Peptic ulcer disease or active/ recent gastrointestinal bleeding within 4 weeks.
    1. Renal dysfunction (creatinine > 1.5 mg/dl) 5) NSAID use during preceding week (acetylsalicylic acid 325 mg daily or less was acceptable) 6) Acute pancreatitis during the 2 weeks before ERCP 7) History of chronic pancreatitis 8) Previous sphincterotomy 9) Refusal to participate in the study.
    1. Pregnancy or lactation 11) Patients undergoing ERCP on an outpatient basis.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
This classification defines three degrees of severity based on the presence or absence of organ failure ( plus its duration ) and of local or systemic complications.within 24 hours Post ERCP
1) Frequency of Post-ERCP Pancreatitis, defined according to the revised Atlanta classification.within 24 hours Post ERCP
Secondary Outcome Measures
NameTimeMethod
1) Incidence of Delayed Post - ERCP pancreatitis ( 24 hours after ERCP )2) Severity of PEP

Trial Locations

Locations (1)

SMS Medical college, Jaipur

🇮🇳

Jaipur, RAJASTHAN, India

SMS Medical college, Jaipur
🇮🇳Jaipur, RAJASTHAN, India
Dr Rishabh gupta
Principal investigator
9588248715
rishabh1313@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.